emergentbiosolutionsaa7f






Certain identified information has been excluded from the exhibit because it is both (i) not  material and (ii) is the type of information that the registrant treats as private or confidential.  Double asterisks denote omissions.  Exhibit 10.14      CHANGE ORDER NO. 5 TO WORK ORDER #5997-01 – [**] STUDY  This Change Order No. 5 entitled — [**] STUDY (“Change Order No. 5”) effective as of  September 16, 2020 (“Change Order No. 5 Effective Date”) to Work Order #5997-01 by and  between AstraZeneca Pharmaceuticals LP (“Astrazeneca”) and Emergent Manufacturing  Operations Baltimore, LLC (“Service Provider”) hereby adds to the scope of Services set forth  in Work Order #5997-01 entered into by the Parties pursuant to the Master Services Agreement  dated July 24, 2020 (the “Master Services Agreement”).  Capitalized terms used in this Change  Order that are not otherwise defined herein have the meanings given to them in the Master Services  Agreement.  In consideration of the mutual promises contained therein and herein and for other good  and valuable consideration the receipt and adequacy of which each of the Parties does hereby  acknowledge, the Parties hereby agree as follows:  1. Purpose and Description of Change.  The purpose of this Change Order No. 5 is to further  add to the Services set forth in Work Order #5997-01.  In addition to the Services set  forth in Work Order #5997-01(including without limitation, within prior Change Orders),  Service Provider will render to Astrazeneca the following Services:  This [**] study will be performed by the Service Provider.  The intent of this study will be to  evaluate the [**] characteristics.  [**].  Test   [**]  [**] [**] [**] [**] [**] [**]  [**] [**] [**] [**] [**] [**] [**]  [**] [**] [**] [**] [**] [**] [**]  [**] [**] [**] [**] [**] [**] [**]    2. Deliverables.  2.1 Certificate of Analysis (COA) and a final study report  3. Service Fees.  3.1 In addition to fees set forth in Work Order 5997-01 and in prior Change Orders, the  additional fees due to Service Provider for Services included under this Change Order No. 5 shall  be as follows:  





 






CONFIDENTIAL AND PROPRIETARY    [**]  Qty Task Deliverable Direct Fees  Est. Pass Through  Costs Line Total  [**] [**] [**] [**] [**] [**]          [**]  [**] [**] [**]   [**]  [**] [**] [**]   [**]  [**] [**] [**]   [**]  [**] [**] [**]   [**]  [**] [**] [**]   [**]  [**] [**] [**]   [**]  [**] [**] [**]  Subtotal [**] [**] [**]    The estimated pass through costs are exclusive of the administrative fee.  The administrative fee  of [**]% will be added to the actual cost of the pass-through costs.  3.2 Astrazeneca shall pay Service Provider all fees and costs set forth in this Change Order in  accordance with the following payment schedule: (a) all fees are payable [**]% upfront upon  initiation of the specified activity or task, with the remaining [**]% payable upon completion of  the applicable activity or task; and (b) all pass-through costs plus the administrative fee of [**]%  are payable [**]% upon order placement for the materials or services, with the remaining [**]%  payable upon Service Provider’s receipt of the materials or services.  4. Miscellaneous.  Except as amended herein, all terms and conditions of Work Order  5997-01 remain unchanged and in full force and effect.  IN WITNESS THEREOF, the authorized representatives of the Parties have executed this Change  Order as of the Change Order Effective Date.    ASTRAZENECA PHARMACEUTICALS LP  BY:  /s/ Michelle Vincent   Name: Michelle Vincent  Title: Supplier Relationship Manager  Date: Oct 2, 2020  EMERGENT MANUFACTURING OPERATIONS  BALTIMORE, LLC  BY:  /s/ Jon Lenihan   Name Jon Lenihan  Title: Sr. Dir., Head of Sales & BD  Date: Sep 30, 2020